New advances in beta-blocker therapy in heart failure

Frontiers in Physiology

Volumn 4 NOV, Issue , 2013, Pages

  Barrese, Vincenzo ^a   Taglialatela, Maurizio ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

Author keywords

beta blockers; Clinical trials as topic; Elderly patients; Heart failure; Pharmacogenomics

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CATECHOLAMINE; CYTOCHROME P450 2D6; CYTOKINE; ENALAPRIL; G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 5; GLUCURONOSYLTRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; PLACEBO; PROTEIN UGT1A; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ADRENERGIC STIMULATION; BETA ADRENERGIC RECEPTOR BLOCKING; CARDITIS; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG TOLERABILITY; HEART AFTERLOAD; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART PRELOAD; HEART STRESS; HUMAN; INTRINSIC SYMPATHOMIMETIC ACTIVITY; MORTALITY; NEUROENDOCRINE SYSTEM; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHARMACOGENOMICS; PHYSICAL CHEMISTRY; PRACTICE GUIDELINE; REVIEW; SYSTOLE; VASOCONSTRICTION; VASODILATATION;

EID: 84889668219     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2013.00323     Document Type: Review

References (46)

1. (1994). A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 90, 1765-1773. doi: 10.1161/01.CIR.90.4.1765
2. (1999). The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9-13. doi: 10.1016/S0140-6736(98)11181-9
3. Akhter, S. A., Skaer, C. A., Kypson, A. P., McDonald, P. H., Peppel, K. C., Glower, D. D., et al. (1997). Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc. Natl. Acad. Sci. U.S.A. 94, 12100-12105. doi: 10.1073/pnas.94.22.12100
4. Baudhuin, L. M., Miller, W. L., Train, L., Bryant, S., Hartman, K. A., Phelps, M., et al. (2010). Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure analyses were performed to compare the genotype to the metoprolol or carvedilol response status and dose. Am. J. Cardiol. 106, 402-408. doi: 10.1016/j.amjcard.2010.03.041
5. Beta-Blocker Evaluation of Survival Trial Investigators. (2001). A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. 344, 1659-1667. doi: 10.1056/NEJM200105313442202
6. Bogoyevitch, M. A., Andersson, M. B., Gillespie-Brown, J., Clerk, A., Glennon, P. E., Fuller, S. J., et al. (1996). Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. Biochem. J. 314, 115-121.
7. Bristow, M. R. (2000). Beta-adrenergic receptor blockade in chronic heart failure. Circulation 101, 558-569. doi: 10.1161/01.CIR.101.5.558
8. Bristow, M. R., Larrabee, P., Minobe, W., Roden, R., Skerl, L., Klein, J., et al. (1992). Receptor pharmacology of carvedilol in the human heart. J. Cardiovasc. Pharmacol 19(suppl. 1), S68-S80. doi: 10.1097/00005344-199219001-00014
9. Chatterjee, S., Biondi-Zoccai, G., Abbate, A., D'Ascenzo, F., Castagno, D., Van Tassell, B., et al. (2013). Lichstein, E. Benefits of ß blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 16, 346-355. doi: 10.1136/bmj.f55
10. Dedkov, E. I., Christensen, L. P., Weiss, R. M., and Tomanek, R. J. (2005). Reduction of heart rate by chronic beta1-adrenoceptor blockade promotes growth of arterioles and preserves coronary perfusion reserve in postinfarcted heart. Am. J. Physiol. Heart Circ. Physiol. 288, H2684-H2693. doi: 10.1152/ajpheart.01047.2004
11. Del Sindaco, D., Tinti, M. D., Monzo, L., and Pulignano, G. (2010). Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure. Clin. Interv. Aging 5, 381-393. doi: 10.2147/CIA.S4482
12. DiNicolantonio, J. J., Lavie, C. J., Fares, H., Menezes, A. R., and O'Keefe, J. H. (2013). Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol Am. J. Cardiol. 111, 765-769. doi: 10.1016/j.amjcard.2012.11.031
13. Edes, I., Gasior, Z., and Wita, K. (2005). Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur. J. Heart Fail. 7, 631-639. doi: 10.1016/j.ejheart.2004.10.015
14. Ellison, K. E., and Gandhi, G. (2005). Optimising the use of beta-adrenoceptor antagonists in coronary artery disease. Drugs 65, 787-797. doi: 10.2165/00003495-200565060-00006
15. Engelhardt, S., Hein, L., Wiesmann, F., and Lohse, M. J. (1999). Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 96, 7059-7064. doi: 10.1073/pnas.96.12.7059
16. Fiuzat, M., Neely, M. L., Starr, A. Z., Kraus, W. E., Felker, G. M., Donahue, M., et al. (2013). Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. Eur. J. Heart Fail. 15, 258-266. doi: 10.1093/eurjhf/hfs175
17. Flather, M. D., Shibata, M. C., Coats, A. J., Van Veldhuisen, D. J., Parkhomenko, A., Borbola, J., et al. (2005). Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. 26, 215-225. doi: 10.1093/eurheartj/ehi115
18. Goodman, and Gilman's. (2011). The Pharmacological Basis of Therapeutics, 12th Edn. (New York, NY: McGraw-Hill), ISBN: 978-0-07-162442-8
19. Granneman, J. G. (2001). The putative beta4-adrenergic receptor is a novel state of the beta1-adrenergic receptor. Am. J. Physiol. Endocrinol. Metab. 280, E199-E202.
20. Hjalmarson, A., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., et al. (2000). Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283, 1295-1302. doi: 10.1001/jama.283.10.1295
21. Iaccarino, G., Tomhave, E. D., Lefkowitz, R. J., and Koch, W. J. (1998). Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation 98, 1783-1789. doi: 10.1161/01.CIR.98.17.1783
22. Iwase, M., Bishop, S. P., Uechi, M., Vatner, D. E., Shannon, R. P., Kudej, R. K., et al. (1996). Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gsa overexpression. Circ. Res. 78, 517-524. doi: 10.1161/01.RES.78.4.517
23. Jacob, S., Rett, K., Wicklmayr, M., Agrawal, B., Augustin, H. J., and Dietze, G. J. (1996). Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J. Hypertens. 14, 489-494. doi: 10.1097/00004872-199604000-00012
24. Kubon, C., Mistry, N. B., Grundvold, I., Halvorsen, S., Kjeldsen, S. E., and Westheim, A. S. (2011). The role of beta-blockers in the treatment of chronic heart failure. Trends Pharmacol. Sci. 32, 206-212. doi: 10.1016/j.tips.2011.01.006
25. Levin, M. C., Marullo, S., Muntaner, O., Andersson, B., and Magnusson, Y. (2002). The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J. Biol. Chem. 277, 30429-30435. doi: 10.1074/jbc.M200681200
26. Lohse, M. J., Engelhardt, S., and Eschenhagen, T. (2003). What is the role of beta-adrenergic signaling in heart failure? Circ. Res. 93, 896-906. doi: 10.1161/01.RES.0000102042.83024.CA
27. Lymperopoulos, A., Rengo, G., and Koch, W. G. (2013). Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ. Res. 113, 739-753. doi: 10.1161/CIRCRESAHA.113.300308
28. Lymperopoulos, A., Rengo, G., Funakoshi, H., Eckhart, A. D., and Koch, W. J. (2007). Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat. Med. 13, 315-323. doi: 10.1038/nm1553
29. Mentz, R. J., Wojdyla, D., Fiuzat, M., Chiswell, K., Fonarow, G. C., and O'Connor, C. M. (2013). Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am. J. Cardiol. 111, 582-587. doi: 10.1016/j.amjcard.2012.10.041
30. Murray, K. T., Reilly, C., Koshakji, R. P., Roden, D. M., Lineberry, M. D., Wood, A. J., et al. (1990). Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade. J. Clin. Invest. 85, 836-842. doi: 10.1172/JCI114510
31. Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., et al. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334, 1349-1355. doi: 10.1056/NEJM199605233342101
32. Packer, M., Fowler, M. B., Roecker, E. B., Coats, A. J., Katus, H. A., Krum, H., et al. (2002). Effect of carvedilol on the morbidity of patients with severe chronic heart failure results of the carvedilol prospective randomized cumulative survival (COPERNICUS). Circulation 106, 2194-2199. doi: 10.1161/01.CIR.0000035653.72855.BF
33. Poole-Wilson, P. A., Swedberg, K., Cleland, J. G., Di Lenarda, A., Hanrath, P., Komajda, M., et al. (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362, 7-13. doi: 10.1016/S0140-6736(03)13800-7
34. Rengo, G., Cannavo, A., Liccardo, D., Zincarelli, C., de Lucia, C., Pagano, G., et al. (2013). Vascular endothelial growth factor blockade prevents the beneficial effects of ß-blocker therapy on cardiac function, angiogenesis and remodeling in heart failure. Circ. Heart Fail. doi: 10.1161/CIRCHEARTFAILURE.113.000329
35. Rengo, G., Lymperopoulos, A., Leosco, D., and Koch, W. J. (2011). GRK2 as a novel gene therapy target in heart failure. J. Mol. Cell. Cardiol. 50, 785-792. doi: 10.1016/j.yjmcc.2010.08.014
36. Rengo, G., Lymperopoulos, A., Zincarelli, C., Femminella, G., Liccardo, D., Pagano, G., et al. (2012a). Blockade of ß-adrenoceptors restores the GRK2-mediated adrenal a(2) -adrenoceptor-catecholamine production axis in heart failure. Br. J. Pharmacol. 166, 2430-2440. doi: 10.1111/j.1476-5381.2012.01972.x
37. Rengo, G., Perrone-Filardi, P., Femminella, G. D., Liccardo, D., Zincarelli, C., de Lucia, C., et al. (2012b). Targeting the ß-adrenergic receptor system through G-protein-coupled receptor kinase 2: a new paradigm for therapy and prognostic evaluation in heart failure: from bench to bedside. Circ. Heart Fail. 5, 385-391. doi: 10.1161/CIRCHEARTFAILURE.112.966895
38. Rockman, H. A., Chien, K. R., Choi, D. J., Iaccarino, G., Hunter, J. J., and Ross, J. Jr. (1998). Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc. Natl. Acad. Sci. U.S.A. 95, 7000-7005. doi: 10.1073/pnas.95.12.7000
39. Rozec, B., Quang, T. T., Noireaud, J., and Gauthier, C. (2006). Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta. Br. J. Pharmacol. 147, 699-706. doi: 10.1038/sj.bjp.0706648
40. Talameh, J. A., and Lanfear, D. E. (2012). Pharmacogenetics in chronic heart failure: new developments and current challenges. Curr. Heart Fail. Rep. 9, 23-32. doi: 10.1007/s11897-011-0076-2
41. Talameh, J. A., McLeod, H. L., Adams, J. R. K. F., and Patterson, J. H. (2012). Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new. J. Card. Fail. 18, 338-349. doi: 10.1016/j.cardfail.2012.01.002
42. Talber, R. L. (2004). Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. Heart Fail. Rev. 9, 131-137. doi: 10.1023/B:HREV.0000046368.08825.20
43. The CAPRICORN Investigators. (2001). Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357, 1385-1390. doi: 10.1016/S0140-6736(00)04560-8
44. Waagstein, F., Bristow, M. R., Swedberg, K., Camerini, F., Fowler, M. B., Silver, M. A., et al. (1993). Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 342, 1441-1446. doi: 10.1016/0140-6736(93)92930-R
45. Wachter, S. B., and Gilbert, E. M. (2012). Beta-Adrenergic receptors, from their discovery and characterization through their manipulation to beneficial clinical application. Cardiology 122, 104-112. doi: 10.1159/000339271
46. Willenheimer, R., van Veldhuisen, D. J., Silke, B., Erdmann, E., Follath, F., Krum, H., et al. (2005). Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112, 2426-2435. doi: 10.1161/CIRCULATIONAHA.105.582320